Intact Cord Resuscitation in CDH (CHIC)

January 25, 2023 updated by: University Hospital, Lille

Efficacy of Intact Cord Resuscitation Compared to Immediate Cord Clamping on Cardiorespiratory Adaptation at Birth in Infants With Isolated Congenital Diaphragmatic Hernia (CDH)

Isolated CDH is a rare disease (1/3500) and displays a wide range of severity and outcome. Despite attempts to standardize the management of this disease at birth and during the first months of life, the mortality varies from 20 to 50% according to different hospitals in France and abroad.

Several studies already showed the benefice of late cord clamping at birth on biological and physiological adaptation of newborns to life. Previous works also suggest a possible benefit of this procedure for babies with CDH.

This multicenter randomized clinical study aims to investigate the efficacy of intact cord resuscitation compared to immediate cord clamping on cardiorespiratory adaptation at birth in full term newborn infants with isolated CDH.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

180

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Amiens, France
        • Recruiting
        • CHU Amiens Picardie
      • Lille, France, 59037
        • Recruiting
        • Hop Jeanne de Flandre Chu Lille
      • Nantes, France
        • Recruiting
        • CHU de Nantes -

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 months to 8 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Antenatal diagnosis of CDH
  • No severe additional malformation or chromosomal diseases
  • Full term (>36 weeks gestational age)
  • No inclusion in another antenatal trial
  • Written informed consents from the parents

Exclusion Criteria:

  • Preterm birth less than 37 weeks gestational age
  • Other severe malformation(s) or chromosomal diseases
  • Twin
  • Parents who may have French language understanding difficulties may not participate to the study unless they receive appropriate assistance regarding the understanding of the formal consent forms needed to get included in the study. If included in the study, regarding their French understanding level, the parents may not be proposed the auto questionnaires and interviews led by the psychologist

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Immediate umbilical cord clamping
This group includes newborn infants with isolated CDH who will benefit from the standardized CDH management procedure as described in the French national CDH management guidelines ("Programme National de Soins").The resuscitation maneuvers are started after the umbilical cord is clamped.

In the immediate cord clamping group, the umbilical cord will be clamped within the first 20 seconds after birth and the infant will be transferred to the resuscitation room. The newborn infant will be intubated and mechanically ventilated as quickly as possible on the resuscitation table as recommended in the French "Programme National de Soins".

After cardiorespiratory stabilization (i.e. heart rate>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%), the infant will be transferred to the neonatal intensive care unit (NICU). Oxytocin is infused to the mother as recommended in the local protocol (usually just after birth or cord clamping).

Experimental: Intact cord resuscitation
This group includes newborn infants with isolated CDH who will benefit from the standardized CDH resuscitation maneuvers as described in the French national CDH management guidelines ("Programme National de Soins") before the umbilical cord is clamped. The resuscitation maneuvers are started at birth while the umbilical cord still bridges mother and child.
The umbilical cord will be kept intact during the initial phase of the resuscitation. The infant will be placed on a specifically designed compact trolley with a warmed platform, suitable for commencing resuscitation between the mother's legs in case of vaginal birth or near the operating table beside the mother in case of cesarean section. This trolley will be fully equipped for resuscitation, including a suction device, gas flowmeter/blender, ventilatory support, and monitoring system. Its height can be adjusted in order to position the infant close to the maternal perineum. The infant will be intubated and mechanically ventilated on this trolley. The cord will be clamped once cardiorespiratory stabilization will be obtained (i.e. heart rate>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%) or in case of spontaneous placental expulsion. The infant will be then transferred to the neonatal intensive care unit (NICU).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of infants with APGAR score < 4 at 1 min or < 7 at 5 min.
Time Frame: during the first ten minutes after birth
during the first ten minutes after birth
APGAR score
Time Frame: during the first ten minutes after birth
APGAR at 1, 5 and 10 minutes after birth will be reassessed retrospectively by a final observer. The reassessment will be carried out using a video of the first 10 minutes of life of the newborn filmed with a camera if the parents agree. This video will only record the appearance of babies' bodies and faces
during the first ten minutes after birth

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of postpartum hemorrhage (PPH) defined by blood loss ≥ 500 ml
Time Frame: during the deliverance time
during the deliverance time
Frequency of severe PPH, defined by measured blood loss ≥ 1000 ml
Time Frame: during the deliverance time
during the deliverance time
Blood loss volume after birth
Time Frame: at 15 minutes after birth, at 1hours after birth
the collector bag will have to be left in place at least 15 minutes to have one measure of blood loss at the same time point in all women
at 15 minutes after birth, at 1hours after birth
Frequency of infants with the need for chest compressions
Time Frame: during the deliverance time
during the deliverance time
Frequency of infants with the need for epinephrine administration and/or fluid resuscitation
Time Frame: during the deliverance time
during the deliverance time
Heart rate
Time Frame: at 1, 5, and 10 min after birth and at 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
a pulse oximeter sensor will be placed at the right hand as soon as possible (within the first minute after birth), which then will be connected to a pulse oximeter;
at 1, 5, and 10 min after birth and at 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
plasma lactate concentration
Time Frame: at one hour after birth (H1): at 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
these quantitative variables can be considered as objective markers of early cardiorespiratory adaptation at birth.
at one hour after birth (H1): at 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
changes of global Blood gases parameters
Time Frame: at 1hour , 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
pre- and postductal SpO2,
at 1hour , 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
changes of ventilatory parameters
Time Frame: at 1hour , 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
peak inspiratory pressure
at 1hour , 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
changes of ventilatory parameters
Time Frame: at 1hour , 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
respiratory rate
at 1hour , 24 hours, 48 hours, 72 hours, at 7 days and at 28 days
Volume of fluid resuscitation
Time Frame: during the first 24 hours
during the first 24 hours
Frequency of infants with the need for vasoactive drugs ;
Time Frame: during the first 24 hours
during the first 24 hours
Frequency of infants with the need for pulmonary vasodilator
Time Frame: during the first 24 hours
during the first 24 hours
Hemoglobin concentration
Time Frame: at 24 hours
at 24 hours
Infant mortality rate
Time Frame: at 90-day after birth
at 90-day after birth
Infant morbidity outcomes assessed within the first 90 days after birth
Time Frame: at 90-day after birth
at 90-day after birth
Number of refusal of participating to the protocol.
Time Frame: at the end of the study period (90±7 days after birth)
the reasons for refusal will be recorded : do not want to participate to a research protocol, to not want to be randomized in the immediate cord clamping group, to not want to be randomized in the intact cord resuscitation group;
at the end of the study period (90±7 days after birth)
State Trait Anxiety Inventory (STAI) revised version, form Y
Time Frame: within the first 48 hours after birth, and at the end of the study period (90±7 days after birth).
The STAI is a self-report scale translated in French (1). The scale includes 20 questions, and takes approximately 5 minutes to complete. It is widely used and usually well accepted. Both parents will be requested to answer the questionnaire at two distinct moments. The first will be within the first 48 hours after birth, and the second will be during the medical consultation at the end of the study period (90±7 days after birth).
within the first 48 hours after birth, and at the end of the study period (90±7 days after birth).
the Impact of Event Scale-Revised (IES-R)
Time Frame: during the 7 days prior to completion and at the end of the study period (90±7 days after birth).
The IES-R is made up of 22 items aimed at assessing three main factors of traumatic symptoms (intrusion, avoidance and numbing, and hyperarousal) linked to a specific stressful event. The questions pertain to symptoms occurring during the 7 days prior to completion. The scale usually takes approximately 5 minutes to complete. Parents will be requested to answer the questionnaire during the medical consultation at the end of the study period (90±7 days after birth).
during the 7 days prior to completion and at the end of the study period (90±7 days after birth).
the Intolerance for Uncertainty Scale (EII).
Time Frame: at the end of the study period (90±7 days after birth).
This self-report scale was originally designed in French and includes 27 questions pertaining to the beliefs and representations held by individuals with regards to uncertainty. The scale is usually completed in approximately 10 minutes. Parents will be requested to answer the questionnaire during the medical consultation at the end of the study period (90±7 days after birth).
at the end of the study period (90±7 days after birth).
Semi-structured interviews
Time Frame: at the end of the study period (12 months after birth)
Semi-structured interviews will be proposed by a psychologist to the parents whatever the issue, to assess their personal experience of the resuscitating period at birth, including both early/delayed cord clamping and close/remote resuscitation maneuvers. The interviews tape recordings will be transcribed and then analyzed using thematic coding. The anonymized data will be independently coded by three researchers and compared for consistency of interpretation. The themes that emerged following the final coding will be used for a qualitative analysis of the parental verbatim; Due to he's or her's initial condition (HCD), if the newborn dies before the end of the study, the parents will not be asked to get through the psychological questionnaires and interviews
at the end of the study period (12 months after birth)
the 'faceless' acute neonatal pain scale (FANS)
Time Frame: during intubation
FANS, which doesn't include items on facial expression, is particularly adapted for evaluating acute pain in newborns during intubation. Pain assessment is based on the analysis of limb movement, vocal expression and autonomic reactions, including heart rate variations and the occurrence of bradycardia or desaturation.
during intubation
Cerebral Near-infrared spectroscopy recorded
Time Frame: at H1, H2, H6, H12, H24, H48
at H1, H2, H6, H12, H24, H48
Echographic parameters with the Resistive index and pulsatility index in the anterior cerebral artery
Time Frame: at H6, H24, H24 after the chirurgical CDH repair gesture, H48, D7, D28
at H6, H24, H24 after the chirurgical CDH repair gesture, H48, D7, D28
A parental questionnaire to assess neurological development (ASQ 3 score).
Time Frame: at M6 and M12
at M6 and M12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 8, 2020

Primary Completion (Anticipated)

October 1, 2025

Study Completion (Anticipated)

October 1, 2025

Study Registration Dates

First Submitted

March 18, 2020

First Submitted That Met QC Criteria

June 9, 2020

First Posted (Actual)

June 12, 2020

Study Record Updates

Last Update Posted (Estimate)

January 26, 2023

Last Update Submitted That Met QC Criteria

January 25, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 2018_94
  • 2019-A01030-57 (Other Identifier: ID-RCB number, ANSM)
  • PHRC-18-0234 (Other Identifier: PHRC number, DGOS)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Congenital Diaphragmatic Hernia

Clinical Trials on Immediate umbilical cord clamping

3
Subscribe